Skip to main content
. Author manuscript; available in PMC: 2008 Aug 1.
Published in final edited form as: Cancer Biol Ther. 2008 Apr 24;7(7):1109–1115. doi: 10.4161/cbt.7.7.6192

Figure 4.

Figure 4

Figure 4

The apoptotic effects of IFN-λ requires an intact JAK/STAT pathway (A) Parental 2fTGH cells and individual clones of 2fTGH IFN-λR1 cells were treated with either IFN-α (5 ng/mL) or IFN-λ (5 ng/mL), respectively, over a 24 h period. Detection of pY-STAT1, pY-STAT2, and β-actin expression levels were assessed by Western blot analysis. (B) parental 2fTGH and a panel of individual 2fTGH IFN-λR clones were treated for 72 h with either IFN-α or IFN-λ, respectively and proliferation was measured by MTS assay. (C). Apoptosis was measured in 2fTGH cells and 2fTGH IFN-λR1 clone 5 untreated or treated with IFN-α or IFN-λ for 24 or 48 h. In some experiments, 2fTGH IFN-λR1 cells were pretreated with 40 μM ZVAD-fmk prior to IFN-λ treatment. (D) 2fTGH cells and individual clones of U4A and U3A stably expressing IFN-λR1 were treated with IFN-α (5 ng/mL) or IFN-λ (500 ng/mL), respectively. Proliferation was measured by MTS assay. Data are plotted as the average ± SD of 3 independent experiments.